Last reviewed 2026-04-20 · How we verify

Azacitidine Level -1

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Fatigue
• Constipation
• Diarrhoea
• Headache
• Vomiting
• Epistaxis
• Alanine aminotransferase increased
• Aspartate aminotransferase increased
• Dyspnoea
• Fall
• Insomnia

Key clinical trials

• Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) (PHASE2)
• Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (PHASE1)
• Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (PHASE1, PHASE2)
• Pacritinib With Aza for Upfront Myelodysplastic Syndrome (PHASE1, PHASE2)
• Venetoclax in Patients With MDS or AML in Relapse After AHSCT (PHASE1, PHASE2)
• A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia (PHASE1)
• Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (PHASE1, PHASE2)
• Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Azacitidine Level -1 CI brief — competitive landscape report
• Azacitidine Level -1 updates RSS · CI watch RSS
• Medical College of Wisconsin portfolio CI